From Research at med.fsu.edu Thu Oct 10 11:04:12 2019 From: Research at med.fsu.edu (Med Research) Date: Thu, 10 Oct 2019 15:04:12 +0000 Subject: Collaborative Collision: Big Data Reminder (October 28, 4:00-7:00 p.m., Alumni Center) Message-ID: <60E19361B71BE04F835C1FB3C18361BE01904503E9@FSUCOM128.med.ad.fsu.edu> Dear All, Please see the below invitation from the Office of Proposal Development about this fall's collaborative collision event focused on big data. The event should be worthwhile even if you can only attend for part of the time. The keynote speaker and poster session in the first half is usually the most well-attended, but the second half mingling / networking has been invaluable to the creation of several new teams. Terra ***** Collaborative Collisions are FSU's premier interdisciplinary research networking events, and are routinely attended by 75-100 faculty members from all of our colleges, departments, and research centers. Our goal is to encourage connections that will lead to new and exciting research projects, and participation allows you compete for internal funding through our Collaborative Collision Seed Fund. In addition to networking at the event, a booklet containing a brief description of your research interests, along with your contact information, will be distributed to other attendees and provided on our website. You will also have a research profile poster on display at the event, created by OPD from information you provide about your background and research interests. Big Data is one of the broadest topical areas we have ever covered at a Collaborative Collision event, with applications in practically every academic discipline at FSU, with scores of faculty working on related projects. At the same time, big data has become a hot area for federal funding, with numerous opportunities available from NSF, NIH, the Departments of Defense, Energy, and Education, and the National Endowments for Art and the Humanities. We are especially pleased to announce our Keynote Speaker for this event will be Kate Zwaard, chief of National Digital Initiatives at the United States Library of Congress. Ms. Zwaard leads a new group focused on digital innovation and expanding the use of the digital collections. She previously managed the Digital Repository Development team, contributing leadership, code and a passion for the mission of the agency. Under her technical direction, the Library of Congress ingested three petabytes (equivalent to 3 million gigabytes) of digital collections, including web archives, the first born-digital manuscript collections, 10 million Chronicling America newspaper pages and three-fourths of a trillion tweets. If you have not already, please sign up now: https://www.research.fsu.edu/research-offices/opd/collaborative-collision/registration-page/ [cid:image001.png at 01D57F5A.72424EB0] -------------- next part -------------- An HTML attachment was scrubbed... URL: -------------- next part -------------- A non-text attachment was scrubbed... Name: image001.png Type: image/png Size: 145171 bytes Desc: image001.png URL: From Research at med.fsu.edu Thu Oct 24 17:36:31 2019 From: Research at med.fsu.edu (Med Research) Date: Thu, 24 Oct 2019 21:36:31 +0000 Subject: Weekly Funding Opportunities Message-ID: <60E19361B71BE04F835C1FB3C18361BE019045699A@FSUCOM128.med.ad.fsu.edu> The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications on the influence and intersection of sex and gender in health and disease including: (1) research applications that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the new 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women." The awards under this FOA will be administered by NIH ICs using funds that have been made available through the Office of Research on Women's Health (ORWH) and the scientific partnering Institutes and Centers across NIH. Due November 25, 2019; November 25, 2020; and November 26, 2021. Med-RA deadline to receive draft documents for November 2019 deadline: November 12. Muscular Dystrophy Association: Discovery Research and Translational Research Discovery Research Grants Discovery research includes the search for understanding the causes of disease, unraveling pathways involved in disease, identifying novel drug targets, and testing new strategies to treat disease. The goal for discovery research is to form a solid foundation that informs and accelerates all subsequent drug development. Since each rare disease poses unique challenges to therapy development, discovery research may include various types of studies related to the unmet needs of each disorder including the creation of improved disease models, biomarker discovery, and the identification of the genetic causes of disease, among others. Discovery Research Grants are awarded to independent, established investigators to accelerate progress toward understanding and treating neuromuscular disease and total $100,000 per year for one to three years. In a very limited number of cases, awards will exceed $100,000 per year, but pre-approval is required before letter of intent submission. Translational Research Grants MDA's translational research program represents an innovative way to fund research that's designed to move new drug targets into the clinic as rapidly and efficiently as possible. The program was developed in response to the increasing number of promising therapeutic avenues for neuromuscular diseases that have developed from MDA's discovery research program. MDA Venture Philanthropy is the Muscular Dystrophy Association's drug development program, which is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. MVP funds projects from proof-of-principle studies through phase 2 trials. For-profit entities are required to contribute funds that match or exceed MDA's contribution. MDA will negotiate return on investment. Projects funded by MVP are milestone-driven projects, with funds released according to the completion of pre-agreed upon sections of the project. Letter of intent due December 1, 2019. Med-RA deadline to receive draft documents: November 13. Cancer Intervention and Surveillance Modeling Network (CISNET) (U01 Clinical Trial Not Allowed) This funding opportunity announcement (FOA) is a continuation of Cancer Intervention and Surveillance Modeling Network (CISNET - https://cisnet.cancer.gov) program. This FOA invites multiple PD/PI applications for collaborative research projects using simulation and other modeling techniques for specific cancer types. The proposed research is expected to generate sophisticated, evidence-based decision tools that could inform international/national/regional/local decisions on the most efficient utilization of existing and emerging technologies and strategies for the control of cancer. Due December 10, 2019. Med-RA deadline to receive draft documents: November 28. Environmental Risks for Psychiatric Disorders: Biological Basis of Pathophysiology (R21 / R01 Clinical Trial Not Allowed) R01 R21 The purpose of these funding opportunity announcements (FOAs) is to stimulate research to understand the biological basis by which environmental exposures alter brain and behavioral functioning to increase risk for psychiatric disorders with onset in late childhood, adolescence, or early adulthood. A range of approaches are encouraged, from mechanistic experiments using whole organism models or in vitro and in vivo systems to human studies that add new data collection activities and/or make use of extant data or biospecimens. Investigations that further advance our understanding of the joint contribution of genes and environment in the risk for psychiatric disorders are welcomed. Applications should address either categorically defined psychiatric diagnoses and/or continuous traits expressed in the general population. Applicants are encouraged to propose studies that consider co-occurring psychiatric conditions and potential shared etiologies. It is anticipated that knowledge gained from the research supported by these FOAs will inform the development of improved intervention, prevention and/or therapeutic strategies. Due December 10, 2019; November 16, 2020; and November 16, 2021. Med-RA deadline to receive draft documents for December 2019 deadline: November 28. Strategies to Improve Health Outcomes and to Reduce Disparities in Rural Populations (R01 Clinical Trial Optional) This RFA encourages research to promote a greater understanding of the challenges faced by rural population groups, for the development (or adoption/adaptation) of evidence-based interventions that can reduce health risks faced by rural Americans. Both prevention and treatment interventions are needed to address rural health issues. Prevention strategies should address and measure reductions in risk factors and enhancement of protective factors, while treatment approaches would seek to measure and address amelioration of health in individuals living with existing conditions. To accomplish these goals, the research community will be encouraged to use a wide range of culturally appropriate methodological approaches that can enhance access to and acceptability of interventions in rural settings, such as telehealth and community-based prevention research, where appropriate. It is our hope that research supported under this RFA will contribute to our knowledge of the sustainability of health promotion and disease prevention strategies in rural settings. Due December 13, 2019. Med-RA deadline to receive draft documents: November 30. American Federation for Aging Research: Research Grants for Junior Faculty The major goal of this program is to assist in the development of the careers of junior investigators committed to pursuing careers in the field of aging research. GMRF and AFAR support research projects concerned with understanding the basic mechanisms of aging rather than disease-specific research. Projects investigating age-related diseases are supported if approached from the point of view of how basic aging processes may lead to these outcomes. Projects concerning mechanisms underlying common geriatric functional disorders are also encouraged, as long as these include connections to fundamental problems in the biology of aging. Projects that deal strictly with clinical problems such as the diagnosis and treatment of disease, health outcomes, or the social context of aging are not eligible. Examples of potentially fundable areas of research include, but are not limited to: * Aging and immune function * Stem cell aging * Inflammation * Genetic control of longevity * Neurobiology and neuropathology of aging * Invertebrate or vertebrate animal models * Cardiovascular aging * Aging and cellular stress response * Metabolic and endocrine changes Letter of intent due December 16, 2019. Med-RA deadline to receive draft documents: December 4. Glenn Foundation for Medical Research Breakthroughs in Gerontology (BIG) Award Sponsored by the Glenn Foundation for Medical Research, in collaboration with the American Federation for Aging Research (AFAR), the "Breakthroughs in Gerontology (BIG)" initiative provides timely support to a small number of research projects that are relatively high risk but which offer significant promise of yielding transforming discoveries in the fundamental biology of aging. Projects which build on early discoveries that show translational potential for clinically-relevant strategies, treatments and therapeutics, addressing human aging and health span are also considered. Projects that focus on specific diseases or on assessment of health care strategies will receive lower priority, unless the research plan makes clear and direct connections to fundamental issues in the biology of aging and/or on the translational aspects of basic discovery to human aging and healthspan. Two three-year awards will be made in 2020, at the level of $300,000 total ($100,000 per year), of which a maximum of 8% may be used for indirect expenses or institutional overhead. The amount and the duration of the award may be modified if during the review process or at the funding stage it is evident that such modifications would better serve the objectives of the program. Letter of intent due December 16, 2019. Med-RA deadline to receive draft documents: December 4. Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CPDPC-CCs) (U01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) invites U01 applications for the continuation of the consortium to study Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CCs) and one Coordination and Data Management Center (CDMC). This FOA will accept both clinical studies and clinical trials that contribute to the research objectives of the CPDPC. The Consortium, since its establishment in Fall 2015, has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. To effectively contribute to the ongoing CPDPC clinical studies, each CC application should include researchers and clinicians with multi-disciplinary expertise to match the objectives of the CPDPC (see https://cpdpc.mdanderson.org/clinicalstudies.html). Research CCs will be expected to share results freely within Consortium and to develop trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the CCs. Due December 17, 2019. Med-RA deadline to receive draft documents: December 4. Consortium on the Neurobiology of Adolescent Drinking in Adulthood (NADIA) Research Projects (Collaborative U01 - Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) solicits research cooperative agreements as part of the Neurobiology of Adolescent Drinking in Adulthood (NADIA) consortium to elucidate persistent changes in complex brain function-behavior relationships following adolescent alcohol exposure. The purpose of this FOA is to support collaborative research projects (U01) focusing on research efforts across different research institutions investigating the consequences of repeated adolescent alcohol exposure on brain maturation and adult abilities. Since NIAAA is interested in supporting experimental studies on the effects of controlled alcohol doses and exposure periods, this initiative is limited to animal studies only. Due December 18, 2019. Med-RA deadline to receive draft documents: December 4. R40 Maternal and Child Health Secondary Data Analysis Research (MCH SDAR) Program The R40 MCH SDAR Program supports applied MCH research that exclusively utilizes the secondary analyses of existing publicly available and accessible national databases and/or administrative records to improve the health and well-being of MCH populations. The program accelerates the pace of research in a cost-effective way by providing researchers with an opportunity to pose new research questions, test new hypotheses, and determine pathways and feasibility of interventions using existing data sets, rather than conducting primary data collection, which is both costly and time-consuming. Findings from the research supported by the R40 MCH SDAR Program are expected to: * Strengthen and expand topics addressed by the Title V MCH Services Block Grant National Performance Domains (see Appendix C). For more background materials on the Title V Program, see: http://mchb.hrsa.gov/programs/titlevgrants/index.html. By supporting research on MCH populations, the R40 MCH SDAR Program aims to inform HRSA Maternal and Child Health Bureau's (MCHB's) other investments and programs, see: https://mchb.hrsa.gov/maternal-child-health-initiatives; * Address HRSA MCHB's Strategic Research Issues (see Appendix A) such as improving public health systems and infrastructure, reducing health inequalities, increasing quality of and access to care, and/or promoting the health of MCH populations; * Address Healthy People 2020 objectives that are relevant to the proposal. Proposals should connect the proposed topic with the Healthy People 2020 objectives; * Address HRSA's clinical priorities, namely, opioid use disorder, mental health, telehealth, childhood obesity, and maternal mortality. Study findings will further develop the evidence base for the above clinical priority topics; and * Address emerging research topics of regional and national significance that highlight new data, knowledge, evidence, and strategies for addressing the burden of diseases that affect MCH populations. HRSA expects each R40 MCH SDAR award recipient to complete the following major activities: * Conduct applied or translational research on critical and emerging MCH issues through appropriate secondary analyses of existing national databases and/or administrative records that are aligned with research goals; * Develop and submit a dissemination plan for the distribution of research findings and products to scientific, professional, and lay audiences. Due January 8, 2020. Med-RA deadline to receive draft documents: January 2. NSF Law & Science The Law & Science Program considers proposals that address social scientific studies of law and law-like systems of rules, as well as studies of how science and technology are applied in legal contexts. The Program is inherently interdisciplinary and multi-methodological. Successful proposals describe research that advances scientific theory and understanding of the connections between human behavior and law, legal institutions, or legal processes; or the interactions of law and basic sciences, including biology, computer and information sciences, STEM education, engineering, geosciences, and math and physical sciences. Scientific studies of law often approach law as dynamic, interacting with multiple arenas, and with the participation of multiple actors. Fields of study include many disciplines, and often address problems including, though not limited, to: * Crime, Violence, and Policing * Cyberspace * Economic Issues * Environmental Science * Evidentiary Issues * Forensic Science * Governance and Courts * Human Rights and Comparative Law * Information Technology * Legal and Ethical Issues related to Science * Legal Decision Making * Legal Mobilization and Conceptions of Justice * Litigation and the Legal Profession * Punishment and Corrections * Regulation and Facilitation of Biotechnology (e.g., Gene Editing, Gene Testing, Synthetic Biology) and Other Emerging Sciences and Technologies * Use of Science in the Legal Processes Due January 15, 2020 and August 3, 2020. Med-RA deadline to receive draft documents for January 2020 deadline: January 2. Improving the Reach and Quality of Cancer Care in Rural Populations (R01 Clinical Trial Required) The purpose of this Funding Opportunity Announcement (FOA) is to reduce the burden of cancer and improve the quality of cancer care in rural areas among low-income and/or underserved populations. The FOA encourages two types of applications: (1) observational research that includes intervention pilot testing to understand and address predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations; or (2) intervention research to address known predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations. The focus for observational studies with pilot testing is understanding and addressing the predictive and/or mediating role of social determinants of health, barriers to care, and treatment. The focus for intervention research is addressing quality of care related to cancer diagnosis, treatment and/or survivorship. Most existing cancer control interventions are not ready for direct implementation and dissemination in low-income rural areas, so applications should seek to develop, adapt, implement, and test interventions. Due January 15, 2020. Med-RA deadline to receive draft documents: January 2. Maximizing Investigators' Research Award (R35 - Clinical Trial Optional) The Maximizing Investigators' Research Award (MIRA) provides support for the program of research in an investigator's laboratory that is within the mission of NIGMS. The goal of MIRA is to increase the efficiency and efficacy of NIGMS funding. It is anticipated that this program will: * Increase the stability of funding for NIGMS-supported investigators, which could enhance their ability to take on ambitious scientific projects and approach problems more creatively; * Increase flexibility for investigators to follow important new research directions within the NIGMS mission as opportunities arise, rather than being bound to specific aims proposed in advance of the studies; * More widely distribute funding among the nation's highly talented and promising investigators to increase overall scientific productivity and the chances for important breakthroughs; * Reduce the time spent by researchers writing and reviewing grant applications, allowing them to spend more time conducting research; * Enable investigators to devote more time and energy to mentoring trainees in a more stable research environment. This FOA allows both new applications from eligible NIGMS-funded investigators and renewal applications from current established and early-stage MIRA grantees. Due January 17, 2020; May 18, 2020; January 19, 2021; May 17, 2021; January 18, 2022; and May 17, 2022. Med-RA deadline to receive draft documents for January 2020 deadline: January 6. Low Cost Detection of Cognitive Decline in Clinical Settings (R61 / R33 / R01Clinical Trial Required) R61 / R33 This Funding Opportunity Announcement (FOA) invites applications to pursue development and validation studies of cognitive screening instruments or assessments in clinical settings and to translate these screening and assessment tools into electronic health record (EHR) systems that can assist physicians in making clinically meaningful care recommendations for patients experiencing cognitive decline. This FOA will support an R61 pilot phase (Stage I) which will allow researchers to develop and validate tools for cognitive assessment and then create scalable, tailored interventions for patients experiencing cognitive decline to help overcome barriers to uptake. If successful, researchers may transition to an R33 phase (Stage IV) for implementation of pragmatic trials. All applicants are required to address health disparities. This FOA does not require preliminary data. R01 This Funding Opportunity Announcement (FOA) invites applications to pursue validation studies of cognitive screening instruments or assessments in clinical settings and to translate these screening and assessment tools into electronic health record (EHR) systems that can assist physicians in making clinically meaningful care recommendations for patients experiencing cognitive decline. This FOA requires prior preliminary data gathered during the development of cognitive screening tools and/or assessments. This FOA will also support research to validate these tools as well as their implementation in large clinical settings. Plans for validation of cognitive impairment against relevant Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) biomarkers are encouraged but not required Due January 30, 2020. Med-RA deadline to receive draft documents: January 16. Dementia Care: Home- and Community-Based Services (HCBS) (R21 / R01 Clinical Trial Not Allowed) R21 R01 This Funding Opportunity Announcement (FOA) invites applications seeking to examine the outcomes of care for persons with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) by identifying home- and community-based services (HCBS) used, as well as barriers to accessing these types of care and unmet needs of persons with AD/ADRD concerning care and services. Due February 3, 2020. Med-RA deadline to receive draft documents: January 21. NIA Behavioral and Social Research Leaders in Alzheimer's Disease and Its Related Dementias (NIA BSR LEADR) (DP1 - Clinical Trial Not Allowed) The NIA Behavioral and Social Research Leaders in Alzheimer's Disease and Its Related Dementias (NIA BSR LEADR) program supports individual scientists of exceptional creativity who propose to use behavioral and social science perspectives and approaches for highly innovative, impactful, and potentially transformative theoretical, empirical, and clinical research addressing the challenges raised by Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) for individuals, their families, and society. Applications are welcome from individuals with diverse backgrounds. NIA encourages applications on a variety of AD/ADRD topics in which behavioral and social research can contribute, such as dementia care, dementia caregiver research, cognitive and dementia epidemiology, behavioral and social pathways of AD/ADRD, early psychological changes preceding AD/ADRD, prevention of AD/ADRD, and disparities in AD/ADRD or dementia-related outcomes. Responsive applications must reflect a new insight into a potential solution to an important problem related to AD/ADRD that can be addressed with exceptionally innovative or unconventional behavioral and/or social science methods. This initiative is to support investigators who intend to pursue new research directions distinct from those they currently or previously conducted. While the proposed research may have the investigator's prior work and expertise as its foundation, it cannot be a minor extension or scale-up of a current or past research enterprise. Due February 3, 2020. Med-RA deadline to receive draft documents: January 21. Innovations to Foster Healthy Longevity in Low-Income Settings (R03 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) invites applications for research and development to improve functioning and quality of life for the elderly, especially the disabled elderly, living in low- and middle-income countries (LMICs), or to improve functioning and quality of life for low-income, disabled, and isolated elderly living in high-income countries. Applications may address the needs of the elderly directly or indirectly by supporting family or other informal caregivers and service providers. Applications likely to have an impact on a large scale are encouraged. Due February 3, 2020. Med-RA deadline to receive draft documents: January 21. Ethical Issues in Translational Science Research (R01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement is to support research to address ethical issues in translational science research. Collaboration between bioethicists, legal scholars, social scientists, and translational research scientists is encouraged. The focus is to develop knowledge to inform the ethical development, modification, or application of novel findings, technologies, and approaches to improve human health, including their impact on individuals, families, communities, and society. Due February 6, 2020; October 6, 2020; and October 6, 2021. Med-RA deadline to receive draft documents for February 2020 deadline: January 27. Genetic Architecture of Mental Disorders in Ancestrally Diverse Populations (Collaborative U01 and Single-site U01 Clinical Trial Not Allowed) Collaborative U01 Single-site U01 These Funding Opportunity Announcements seek applications proposing coordinated efforts to accelerate gene discovery for psychiatric disorders in cohorts of non European ancestry to advance the important goal of global mental health discovery and equity. These FOAs are two of several supporting the "Ending Disparities in Mental Health" (EDIfy-MH) program. Due February 14 , 2020; September 15, 2020; September 15, 2021; and September 15, 2022. Med-RA deadline to receive draft documents for February 2020 deadline: February 3. Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed) This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption. Well-suited applications must offer the potential to accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, prevention or epidemiology, while addressing issues associated with HLBS-related diseases and disorders. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation. Applications considered nonresponsive to the FOA will not be reviewed. Due March 9, 2020; July 9, 2020; March 9, 2021; and July 9, 2021. Med-RA deadline to receive draft documents for March 2020 deadline: February 25. Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with an Exploratory/Developmental Phased Award (R61/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R61 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, permitting accelerated bi-directional research exchange. Due March 17, 2020; July 17, 2020; November 17, 2020; March 17, 2021; July 19, 2021; November 17, 2021; March 17, 2022; July 19, 2022; and November 7, 2022. Med-RA deadline to receive draft documents for March 2020 deadline: March 4. Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Clinical Trials Not Allowed / R01 Basic Experimental Studies with Humans Required) R01 Clinical Trials Not Allowed This funding opportunity announcement (FOA) solicits research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal and human subjects research projects are welcome. Researchers proposing basic science experimental studies involving human participants should consider this FOA's companion for basic experimental studies with humans (below). R01 Basic Experimental Studies with Humans Required This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolatedness. NIH considers such studies as "prospective basic science studies involving human participants" that meet the NIH definition of basic research and fall within the NIH definition of a clinical trials (see, e.g., NOT-OD-19-024) Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Due March 17, 2020 and March 17, 2021. Med-RA deadline to receive draft documents for March 2020 deadline: March 4. Understanding Phage Biology to Support the Development of Bacteriophage Therapy (R21 Clinical Trial Not Allowed) This initiative will support basic and translational research to address knowledge gaps that hinder the development and regulation of bacteriophage used to prevent and treat drug-resistant bacterial infections. Due March 18, 2020. Med-RA deadline to receive draft documents: March 5. Patient Activation for Self-Management of Chronic Conditions (R21 / R01 Clinical Trial Optional) R21 R01 The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the influence of patient activation on self-management of chronic conditions. Due June 5, 2020; February 5, 2021; June 5, 2021; February 5, 2022; June 5, 2022; and February 5, 2023. Med-RA deadline to receive draft documents for June 2020 deadline: May 26. Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Basic Science (R03 Clinical Trials Not Allowed); Archiving and Leveraging Existing Data Sets for Analyses (R03 Clinical Trial Not Allowed); Systems Biology (R03 Clinical Trial Not Allowed) Basic Science R03 This Small Research Grant (R03) will support important and innovative projects focused on basic science approaches to elucidate neurodegenerative mechanisms/pathways of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Proposed projects should ultimately aim to improve the prevention, diagnosis, treatment, and/or care for individuals with AD/ADRD. The program seeks (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support. Archiving and Leveraging Existing Data Sets for Analyses R03 This R03 will support important and innovative projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this FOA will support archiving and leveraging existing data sets for analyses of projects covering a wide array of topics relating to AD/ADRD. The overall goal of this FOA is (i) to encourage the next generation of U.S. researchers to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support. Systems Biology R03 This R03 will support important and innovative system biology projects in which more scientific insight is needed to improve the prevention, diagnosis, treatment, and care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The overall goal of this R03 program is (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups, as well as individuals with disabilities, are always encouraged to apply for NIH support. Standard dates apply. Expires November 17, 2022. Med-RA deadline to receive draft documents for February 16, 2020 standard date: February 3. Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control. Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for February 5, 2020 standard date: January 23. Perception and Cognition Research to Inform Cancer Image Interpretation (R21 / R01 Clinical Trial Optional) R21 R01 The purpose of these Funding Opportunity Announcements is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis. Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for February 5, 2020 R01 standard date: January 23; Med-RA deadline to receive draft documents for February 16, 2020 R21 standard date: February 3. Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed) This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs' (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC will be considered not acceptable to this FOA. Standard dates apply. Expires May 8, 2021. Med-RA deadline to receive draft documents for February 16, 2020 standard date: February 3. Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed) The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed. Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for February 16, 2020 standard date: February 3. Omics-guided Biobehavioral Interventions for Improved Health Outcomes: A Step Forward in Translation (R01 Clinical Trial Optional) The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that harnesses the wealth of advances in the fields of genomics and other omics (e.g., metabolomics, microbiomics, proteomics, transcriptomics, epigenomics, etc.) to incorporate these advances into translatable, personalized biobehavioral interventions for improved health outcomes. Standard dates apply. Expires January 8, 2023. Med-RA deadline to receive draft documents for February 5, 2020 standard date: January 23. Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional) This FOA allows for applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions. Standard dates apply. Expires September 26, 2022. Med-RA deadline to receive draft documents for January 25, 2020 standard date: January 13. Transitions to Excellence in Molecular and Cellular Biosciences Research (Transitions) The Division of Molecular and Cellular Biosciences (MCB) has developed a new opportunity to enable researchers with a strong track record of prior accomplishment to pursue a new avenue of research or inquiry. This funding mechanism is designed to facilitate and promote a PI's ability to effectively adopt empowering technologies that might not be readily accessible in the PI's current research environment or collaboration network. Transformative research likely spans disciplines and minimizing the practical barriers to doing so will strengthen research programs poised to make significant contributions. The award is intended to allow mid-career or later-stage researchers (Associate or Full Professor, or equivalent) to expand or make a transition in their research programs via a sabbatical leave or similar mechanism of professional development and then develop that research program in their own lab. This award will also enable the PI to acquire new scientific or technical expertise, facilitate the investigator's competitiveness, and potentially lead to transformational impacts in molecular and cellular bioscience. The award would fund up to six months of PI salary during the first sabbatical or professional development year, followed by support for continued research for two subsequent years upon the PI's return to normal academic duties. Through this solicitation MCB and NSF hope to develop a novel mechanism that will encourage investigators to expand and/or transition to new research areas aligned with MCB priorities, to increase retention of investigators in science, and to ensure a diverse scientific workforce that remains engaged in active research. Highest funding priority is given to proposals that have outstanding intellectual merit and broader impacts, while proposals with weaknesses in either category (or those that are perceived as likely to have an incremental impact) will not be competitive. Proposals should also demonstrate a strong record of prior accomplishment, a compelling plan for professional development that will enable the PI to forge a new direction in their scholarship, and a strong rationale for why this support is needed for the PI to become competitive in the new research area. Support for the proposed transition from the PI's department, described in a letter from the department chair or equivalent, will also be required. Proposals that do not describe a plan for a transition in research direction will be considered unresponsive. Proposals that are motivated to understand the molecular and cellular basis of disease and disease treatments are not appropriate for the Division and will be returned without review. Proposals addressing major open questions at the intersections of biology with other disciplines, such as physics, chemistry, mathematics, computer sciences, and engineering are of particular interest to the program. Proposals accepted anytime. Med-RA deadline to receive draft documents: Ten business days before submission to sponsor. Forecasts Community-wide Approaches for Healthy Children Department of Health and Human Services Office of the Assistant Secretary for Health Estimated post date: December 6, 2019 Estimated due date: March 6, 2020 The Office of Minority Health (OMH) is offering a funding opportunity to assess the effectiveness of interventions targeted community-wide in order to prevent adverse childhood experiences (ACEs) in racial/ethnic minority and disadvantaged populations. Funding will be used to implement and evaluate prevention approaches that expand or improve upon evidence-based interventions or promising research evidence. OMH will fund awards annually for a project period of up to 2 years. A limited competition among grant recipients making satisfactory progress will be considered for a third year of funding. This funding opportunity builds upon lessons learned from other interventions targeted specifically toward individual youth who have experienced trauma and aligns with an enhanced Departmental focus on primary prevention of ACEs. BACKGROUND: ACEs disproportionately impact racial/ethnic minority children and are linked to negative, lasting outcomes for health and wellbeing and higher health care costs. The effects of ACEs include poor physical health, chronic disease, substance use and mental health issues, unemployment and poverty. ACEs are often associated with a wide range of experiences (e.g. food insecurity, housing insecurity, poverty, community violence), and prevention of ACEs requires community-level responses. State/Tribal/Territorial Partnership Initiative to Document, Sustain and Spread Disparity-Reducing Interventions Department of Health and Human Services Office of the Assistant Secretary for Health Estimated post date: December 6, 2019 Estimated due date: March 6, 2020 The State/Tribal/Territorial Partnership Initiative is a demonstration cooperative agreement to identify best practices for documenting, sustaining and spreading health disparity-reducing interventions in racial and ethnic minority populations to ultimately improve health outcomes. Ultimately, this award is intended to enhance the capacity of state/tribal/territorial government agencies to: (1) Implement a public health quality improvement model that can be applied to any racial or ethnic health disparity area; and (2) Develop needed partnerships to sustain successful interventions after the award period. BACKGROUND INFORMATION: State, tribal and territorial government agencies are uniquely positioned to lead efforts for identifying, sustaining and spreading health disparity-reducing interventions using a public health quality improvement model that can be applied to any preventive or clinical issue. For the State/Tribal/Territorial Partnership Initiative, each awardee will be expected to: (1) Utilize baseline data to produce a health disparities profile on 1 to 2 topics aligned with the Department of Health and Human Services' priority areas (e.g., opioid epidemic, HIV, sickle cell disease, physical activity, hepatitis B and maternal mortality), including the incorporation of any relevant Healthy People 2020 leading health indicator; (2) Implement an evidence-based intervention and/or promising practice in the geographical hotspot(s) consistent with the baseline data; and (3) Create a manuscript of the results and impact of the project, including the awardee's identified best practices for sustaining and spreading successful interventions. Awardees will be expected to partner with state/tribal/territorial government agencies and additional health and/or community-based agencies/organizations. The Office of Minority Health will work closely with awardees, and technical assistance will be available for community partnership development and data collection activities to support the success of projects. To search for additional funding opportunities, please visit CoM's unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: